Soleno Therapeutics, Inc. announced the appointments of Meredith Manning, M.B. A as Chief Commercial Officer. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. Meredith Manning, M.B.A. brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices.

Her expertise spans U.S. and global commercialization, brand building, and go-to-market strategies for products at all lifecycle stages, with significant experience in rare diseases. Prior to joining Soleno, she served as President of the Americas and a member of the U.S. Board of Directors at PharmaEssentia, where she led the U.S. regulatory approval and commercial launch of PharmaEssentia's first product, BESREMi®. Prior to PharmaEssentia, Ms. Manning served as the Chief Commercial Officer at resTORbio and as a vice president of marketing for a seven-brand hemophilia portfolio at Baxter BioScience (now Takeda).

She previously held senior marketing and field leader roles at Vertex and Pfizer. Ms. Manning holds an M.B.A. from the University of Chicago Booth School of Business and a B.A. in political science from Colorado College. Shamim Ruff, M.S. brings more than 25 years of experience in the biopharmaceutical industry, with expertise in both domestic and international regulatory affairs spanning early and late development across multiple therapeutic areas.

She is currently the Chief Regulatory Affairs Officer and SVP, Head of Quality Assurance at Stoke Therapeutics and until recently, she served on the Board of Directors of Reata Pharmaceuticals until their acquisition by Biogen. Prior to Stoke, she served as Chief Regulatory Affairs Officer at Sarepta Therapeutics, where she built the company?s regulatory affairs and quality organizations and was responsible for leading and defining the regulatory strategy for the company?s rare and infectious disease pipelines. Prior to Sarepta, Ms. Ruff served as Vice President, Head of Regulatory Affairs Oncology at Sanofi-Genzyme, leading the global, European and CMC regulatory affairs teams. She has also held increasing senior regulatory roles at Amgen, Abbott and AstraZeneca.

She holds a bachelor?s degree in chemistry and biology from the University of Leicester, UK, and a master?s degree in analytical chemistry from the University of Loughborough, U.K. James Geraghty, J.D., M.S. is an industry leader with over 30 years of strategic and leadership experience focused on the development and commercialization of innovative therapies. Mr. Geraghty serves as the Chairman of the Board of Directors for Orchard Therapeutics plc, Pieris Pharmaceuticals, Inc., and OMass Therapeutics. He is also a member of the Board of Directors for Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He served as an entrepreneur-in-residence at Third Rock Ventures from 2013 to 2016.

Prior to Third Rock Ventures, he served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. During his 20-year tenure at Genzyme, Mr. Geraghty held pivotal roles such as Senior Vice President of International Development, President of Genzyme Europe, and founding president and CEO of Genzyme Transgenics. He holds a J.D. from Yale Law School, M.S. from the University of Pennsylvania and a B.A. from Georgetown University.